Menthol cigarettes likely have health impact: FDA
The U.S. Food and Drug Administration on Tuesday released an independent scientific review about menthol in cigarettes, saying that the mint-flavored cigarettes likely pose a greater public health risk than nonmenthol cigarettes.
Meanwhile, the agency issued what it calls an advance notice of proposed rulemaking, seeking input from the public related to potential regulatory options it might consider, such as establishing tobacco product standards.
“While there is little evidence to suggest that menthol cigarettes are more or less toxic or contribute to more disease risk to the user than nonmenthol cigarettes, adequate data suggest that menthol use is likely associated with increased smoking initiation by youth and young adults,” the FDA evaluation said.
Further, menthol in cigarettes is likely associated with greater addiction. Menthol smokers show greater signs of nicotine dependence and are less likely to successfully quit smoking, it said.
According to the FDA, more than 400,000 deaths per year in the United States are caused by tobacco use. About 30 percent of all adult smokers and more than 40 percent of all youth smokers in the country report smoking menthol cigarettes.
“Menthol cigarettes raise critical public health questions,” FDA Commissioner Margaret Hamburg said in a statement. “The FDA is committed to a science-based approach that addresses the public health issues raised by menthol cigarettes, and public input will help us make more informed decisions about how best to tackle this important issue moving forward.”
The agency said that the notice will be available for public comment for 60 days and that it will consider all comments, data, research, and other information submitted to the docket to determine what, if any, regulatory action with respect to menthol in cigarettes is appropriate.
If the agency decides to issue a rule, the first step in that process would be a Notice of Proposed Rulemaking, which would give the public an opportunity to weigh in on the specifics of the proposed rule, the FDA added.
In addition, the FDA said it will support new research on the differences between menthol and nonmenthol cigarettes as they relate to menthol’s likely impact on smoking cessation and attempts to quit, as well as assessing the levels of menthol in cigarette brands and sub-brands.
The menthol-related studies the FDA is now funding include: whether genetic differences in taste perceptions explain why certain racial and ethnic populations are more likely to use menthol comparing exposure to smoke-related toxins and carcinogens from menthol and nonmenthol cigarettes; and examining the effects of menthol and nonmenthol compounds in various tobacco products on both tobacco addiction and toxicants of tobacco smoke.
Source: Xinhua
Category: Features, Health alert
